IL88779A - Method for producing chimeric immunocompromised mammals - Google Patents

Method for producing chimeric immunocompromised mammals

Info

Publication number
IL88779A
IL88779A IL8877988A IL8877988A IL88779A IL 88779 A IL88779 A IL 88779A IL 8877988 A IL8877988 A IL 8877988A IL 8877988 A IL8877988 A IL 8877988A IL 88779 A IL88779 A IL 88779A
Authority
IL
Israel
Prior art keywords
cells
host
human
tissue
organ
Prior art date
Application number
IL8877988A
Other languages
English (en)
Other versions
IL88779A0 (en
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22476130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL88779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL88779A0 publication Critical patent/IL88779A0/xx
Publication of IL88779A publication Critical patent/IL88779A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL8877988A 1987-12-23 1988-12-23 Method for producing chimeric immunocompromised mammals IL88779A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13717387A 1987-12-23 1987-12-23

Publications (2)

Publication Number Publication Date
IL88779A0 IL88779A0 (en) 1989-07-31
IL88779A true IL88779A (en) 1995-07-31

Family

ID=22476130

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8877988A IL88779A (en) 1987-12-23 1988-12-23 Method for producing chimeric immunocompromised mammals

Country Status (8)

Country Link
EP (1) EP0322240B1 (de)
JP (1) JP2801228B2 (de)
AT (1) ATE119197T1 (de)
AU (1) AU2754888A (de)
DE (1) DE3853201T2 (de)
DK (1) DK720488A (de)
ES (1) ES2071620T3 (de)
IL (1) IL88779A (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981486B2 (ja) * 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3068180B2 (ja) * 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5652373A (en) * 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
EP0438053B1 (de) * 1990-01-15 1999-06-16 Yeda Research And Development Company Limited Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
US5849288A (en) * 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5147784A (en) * 1990-04-12 1992-09-15 Systemix, Inc. T-lymphocyte progenitor cell assay
ATE140480T1 (de) * 1990-05-03 1996-08-15 Systemix Inc Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
WO1991018615A1 (en) * 1990-05-25 1991-12-12 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
DK9091D0 (da) * 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
US5849987A (en) * 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US5804160A (en) * 1991-06-04 1998-09-08 Yeda Research And Development Co. Ltd Animal model for hepatitis virus infection
US5858328A (en) * 1991-06-04 1999-01-12 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
DE69229254T2 (de) * 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US6353150B1 (en) * 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
NL9102122A (nl) * 1991-12-18 1993-07-16 Tno Werkwijze voor het testen van antivirale middelen; daarvoor bruikbare proefdieren.
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
AU5965294A (en) * 1993-01-08 1994-08-15 Exemplar Corporation An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
GB9317766D0 (en) * 1993-08-26 1993-10-13 Agricultural & Food Res Animal models
US5972627A (en) * 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5985660A (en) * 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
AU7236094A (en) * 1994-07-03 1996-01-25 P.N. Gerolymatos S.A. Thymus products and applications
US6455756B1 (en) * 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US6015554A (en) * 1995-06-07 2000-01-18 Systemix, Inc. Method of reconstituting human lymphoid and dendritic cells
AU6223096A (en) * 1995-06-07 1996-12-30 Novartis Ag Immunocompromised animals comprising human synovial tissue
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6429353B1 (en) 1997-03-26 2002-08-06 Reprogen, Inc. Endometriosis mouse model
WO1998044788A2 (en) * 1997-04-09 1998-10-15 Chang Lung Ji Animal model for evaluation of vaccines
CA2332336A1 (en) * 1998-05-26 1999-12-02 Erik Depla Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
WO2011002727A1 (en) * 2009-06-29 2011-01-06 Qingfeng Chen Methods of producing humanized non-human mammals
DK3056082T3 (en) 2009-10-06 2018-12-17 Regeneron Pharma RE-MODIFIED MICE AND INPUT
EP2675271B1 (de) 2011-02-15 2018-06-13 Regeneron Pharmaceuticals, Inc. Humanisierte m-csf-mäuse
AU2013312359B8 (en) 2012-09-07 2019-08-15 Institute For Research In Biomedicine (Irb) Genetically modified non-human animals and methods of use thereof
SG11201502685XA (en) 2012-11-05 2015-05-28 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
SG10202002187WA (en) 2014-05-19 2020-04-29 Regeneron Pharma Genetically modified non-human animals expressing human epo
IL302370B2 (en) 2015-04-13 2025-10-01 Regeneron Pharma Mice genetically engineered to express alpha signal modulator protein and interleukin 15 and methods for using them

Also Published As

Publication number Publication date
EP0322240B1 (de) 1995-03-01
DK720488A (da) 1989-06-24
IL88779A0 (en) 1989-07-31
JP2801228B2 (ja) 1998-09-21
ES2071620T3 (es) 1995-07-01
DE3853201T2 (de) 1995-09-14
EP0322240A2 (de) 1989-06-28
DK720488D0 (da) 1988-12-23
DE3853201D1 (de) 1995-04-06
AU2754888A (en) 1989-06-29
JPH0231632A (ja) 1990-02-01
EP0322240A3 (en) 1990-04-18
ATE119197T1 (de) 1995-03-15

Similar Documents

Publication Publication Date Title
EP0322240B1 (de) Schimäre immunkompromittierende Säugetiere und ihre Verwendung
Pearson et al. Creation of “humanized” mice to study human immunity
US20030182671A1 (en) Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
US5147784A (en) T-lymphocyte progenitor cell assay
EP0469632A1 (de) Modulierte xenogene Organsysteme in einem immunitätsbeeinsträchtigten Wirt
US5639939A (en) Chimeric immunocompromised mammal comprosing vascularized fetal organ tissue
JPWO2004110139A1 (ja) ヒト由来免疫担当細胞の製造方法
US5434341A (en) Xenogeneic lymph node in mammary fat pad
US6455756B1 (en) Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
Turner et al. In utero transplantation of human fetal haemopoietic cells in NOD/SCID mice
Ni et al. Both positive and negative effects on immune responses by expression of a second class II MHC molecule
US11419317B2 (en) Non-human animal having human IL-34 and use Thereof
CN1927137A (zh) 抵制抗供体免疫的移植前适应器官
Giusti et al. Pathological insights of human CD34+ hematopoietic stem cell-engrafted NSG mice: Implications for the safety assessment of cancer immunotherapy drugs
US5516977A (en) Xenogeneic tissue implant in ear pinna
Toribio-Fernandez et al. An in vivo mouse model to measure naive CD4 T cell activation, proliferation and Th1 differentiation induced by bone marrow-derived dendritic cells
US12070021B2 (en) Chimeric mouse comprising stably transplanted bat cells
Chambers et al. Exogenous Mtv-7 superantigen transgene expression in major histocompatibility complex class II IE-mice reconstituted with embryonic stem cell-derived hematopoietic stem cells.
US6548737B1 (en) Transgenic mice deficient in natural killer cells
Dunn et al. Bone marrow failure in PNH
Schultheiss et al. The role of Immune Mechanisms in cardiovascular disease
Lasrado et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis
SNG The Role of MHCI Quality and Quantity in Determining CD8 T cell Development, Survival and Function
JP4441680B2 (ja) 造血器腫瘍のアッセイ方法
Guimond Evaluations of functions of uterine natural killer cells during pregnancy in mice

Legal Events

Date Code Title Description
CB Opposition filed against grant of patent

Free format text: 18.10.95

CO Opposition cancelled (oppos. filed against grant of patent)

Free format text: OPPOSITION CANCELLED ON 12.8.96

KB Patent renewed
RH Patent void
RH1 Patent not in force